 | By OncoBeta GmbH Published: Tietze JK, et al. Clin Nucl Med. 2023;48(10):869–876.
|
 | By OncoBeta GmbH OncoBeta® GmbH, a medical device company specialised in innovative epidermal radioisotope therapies, has confirmed the phase IV international multi-centre study designed to further evaluate the Complete Response Rate of patients with non-melanoma skin...
|
 | By OncoBeta GmbH Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites
|
 | By OncoBeta GmbH OncoBeta® GmbH today announced the Steve Biko Academic Hospital in Pretoria, South Africa, is participating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer).
|
 | By OncoBeta GmbH OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, today announces the Sydney Brachytherapy Group is the first private clinic in NSW performing Rhenium-SCT® for patients with non-melanoma skin cancers...
|
| By OncoBeta GmbH OncoBeta® GmbH today announced King's College Hospital in London, United Kingdom, is the latest medical facility to participate in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of...
|
 | By OncoBeta GmbH OncoBeta® GmbH has announced University Clinic of Rostock is participating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT) – for the treatment of non-melanoma skin cancer [NMSC]) treating its first...
|
 | By OncoBeta GmbH OncoBeta® GmbH today announced Perth's Hollywood Private Hospital in Australia is the latest medical facility to participate in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of...
|
